Literature DB >> 17339268

Trisomy for the Down syndrome 'critical region' is necessary but not sufficient for brain phenotypes of trisomic mice.

Lisa E Olson1, Randall J Roper, Crystal L Sengstaken, Elizabeth A Peterson, Veronica Aquino, Zygmunt Galdzicki, Richard Siarey, Mikhail Pletnikov, Timothy H Moran, Roger H Reeves.   

Abstract

Trisomic Ts65Dn mice show direct parallels with many phenotypes of Down syndrome (DS), including effects on the structure of cerebellum and hippocampus. A small segment of Hsa21 known as the 'DS critical region' (DSCR) has been held to contain a gene or genes sufficient to cause impairment in learning and memory tasks involving the hippocampus. To test this hypothesis, we developed Ts1Rhr and Ms1Rhr mouse models that are, respectively, trisomic and monosomic for this region. Here, we show that trisomy for the DSCR alone is not sufficient to produce the structural and functional features of hippocampal impairment that are seen in the Ts65Dn mouse and DS. However, when the critical region is returned to normal dosage in trisomic Ms1Rhr/Ts65Dn mice, performance in the Morris water maze is identical to euploid, demonstrating that this region is necessary for the phenotype. Thus, although the prediction of the critical region hypothesis was disproved, novel gene dosage effects were identified, which help to define how trisomy for this segment of the chromosome contributes to phenotypes of DS.

Entities:  

Mesh:

Year:  2007        PMID: 17339268     DOI: 10.1093/hmg/ddm022

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  72 in total

1.  OLIG2 Drives Abnormal Neurodevelopmental Phenotypes in Human iPSC-Based Organoid and Chimeric Mouse Models of Down Syndrome.

Authors:  Ranjie Xu; Andrew T Brawner; Shenglan Li; Jing-Jing Liu; Hyosung Kim; Haipeng Xue; Zhiping P Pang; Woo-Yang Kim; Ronald P Hart; Ying Liu; Peng Jiang
Journal:  Cell Stem Cell       Date:  2019-05-23       Impact factor: 24.633

2.  Increased efficiency of the GABAA and GABAB receptor-mediated neurotransmission in the Ts65Dn mouse model of Down syndrome.

Authors:  Alexander M Kleschevnikov; Pavel V Belichenko; Jessica Gall; Lizzy George; Rachel Nosheny; Michael T Maloney; Ahmad Salehi; William C Mobley
Journal:  Neurobiol Dis       Date:  2011-10-17       Impact factor: 5.996

3.  Decreasing the Expression of GABAA α5 Subunit-Containing Receptors Partially Improves Cognitive, Electrophysiological, and Morphological Hippocampal Defects in the Ts65Dn Model of Down Syndrome.

Authors:  Verónica Vidal; Susana García-Cerro; Paula Martínez; Andrea Corrales; Sara Lantigua; Rebeca Vidal; Noemí Rueda; Laurence Ozmen; Maria-Clemencia Hernández; Carmen Martínez-Cué
Journal:  Mol Neurobiol       Date:  2017-07-17       Impact factor: 5.590

4.  The Down syndrome critical region regulates retinogeniculate refinement.

Authors:  Martina Blank; Peter G Fuerst; Beth Stevens; Navid Nouri; Lowry Kirkby; Deepti Warrier; Ben A Barres; Marla B Feller; Andrew D Huberman; Robert W Burgess; Craig C Garner
Journal:  J Neurosci       Date:  2011-04-13       Impact factor: 6.167

5.  Genotype-phenotype correlations in Down syndrome identified by array CGH in 30 cases of partial trisomy and partial monosomy chromosome 21.

Authors:  Robert Lyle; Frédérique Béna; Sarantis Gagos; Corinne Gehrig; Gipsy Lopez; Albert Schinzel; James Lespinasse; Armand Bottani; Sophie Dahoun; Laurence Taine; Martine Doco-Fenzy; Pascale Cornillet-Lefèbvre; Anna Pelet; Stanislas Lyonnet; Annick Toutain; Laurence Colleaux; Jürgen Horst; Ingo Kennerknecht; Nobuaki Wakamatsu; Maria Descartes; Judy C Franklin; Lina Florentin-Arar; Sophia Kitsiou; Emilie Aït Yahya-Graison; Maher Costantine; Pierre-Marie Sinet; Jean M Delabar; Stylianos E Antonarakis
Journal:  Eur J Hum Genet       Date:  2008-11-12       Impact factor: 4.246

Review 6.  Prospects for improving brain function in individuals with Down syndrome.

Authors:  Alberto C S Costa; Jonah J Scott-McKean
Journal:  CNS Drugs       Date:  2013-09       Impact factor: 5.749

7.  Human chromosome 21 orthologous region on mouse chromosome 17 is a major determinant of Down syndrome-related developmental cognitive deficits.

Authors:  Li Zhang; Kai Meng; Xiaoling Jiang; Chunhong Liu; Annie Pao; Pavel V Belichenko; Alexander M Kleschevnikov; Sheena Josselyn; Ping Liang; Ping Ye; William C Mobley; Y Eugene Yu
Journal:  Hum Mol Genet       Date:  2013-09-16       Impact factor: 6.150

8.  Maternal choline supplementation improves spatial mapping and increases basal forebrain cholinergic neuron number and size in aged Ts65Dn mice.

Authors:  Jessica A Ash; Ramon Velazquez; Christy M Kelley; Brian E Powers; Stephen D Ginsberg; Elliott J Mufson; Barbara J Strupp
Journal:  Neurobiol Dis       Date:  2014-06-14       Impact factor: 5.996

Review 9.  Molecular basis of pharmacotherapies for cognition in Down syndrome.

Authors:  Katheleen J Gardiner
Journal:  Trends Pharmacol Sci       Date:  2009-12-04       Impact factor: 14.819

10.  Human chromosome 21-derived miRNAs are overexpressed in down syndrome brains and hearts.

Authors:  Donald E Kuhn; Gerard J Nuovo; Mickey M Martin; Geraldine E Malana; Adam P Pleister; Jinmai Jiang; Thomas D Schmittgen; Alvin V Terry; Katheleen Gardiner; Elizabeth Head; David S Feldman; Terry S Elton
Journal:  Biochem Biophys Res Commun       Date:  2008-04-01       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.